Roctavian

pipeline pipes RD research
Biotech

BioMarin axes 4 candidates, centers R&D around 3 assets

BioMarin is prioritizing three of its “most productive” assets, leaving four candidates on the wayside in a move expected to save up to $60 million.
Gabrielle Masson Apr 25, 2024 10:10am
frog jump launching pad lily pad leap

BioMarin looks to up pace of new drug filings

Sep 12, 2023 3:58pm
DNA helix forming inside a test tube

FDA OKs companion Dx with BioMarin hemophilia gene therapy

Jun 30, 2023 10:35am
layoffs layoff exit cut employees staff downsize workforce reduction

BioMarin lays off 120 employees in bid to save $50M a year

Oct 7, 2022 8:33am